Literature DB >> 26933835

Alzheimer's Disease therapeutics: current and future therapies.

Lin-Ben Gao1, Xiao-Fei Yu, Qin Chen, Dong Zhou.   

Abstract

Pathologically, Alzheimer's Disease is characterized by amyloidal protein plaques that lead to dementia in the elderly population. While advances have been made in therapeutics over the course of the last 20 years, the drugs generally target the symptoms rather than the underlying pathology. Unfortunately, despite the advances, the mechanisms behind Alzheimer's Disease have still not been clearly identified. Some of these current treatments include acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor agonists. Recently, the pathophysiology behind this disease is becoming more clearly understood and this has led to some novel therapeutic targets that may be able to break the barrier and target the underlying disease. In this review, we will discuss Alzheimer's Disease pathology and the pharmacological therapy that has been in use for a long time as well as novel therapies.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26933835

Source DB:  PubMed          Journal:  Minerva Med        ISSN: 0026-4806            Impact factor:   4.806


  24 in total

1.  Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage.

Authors:  Hye-Jae Lee; Elizabeth E Roughead; Euna Han; Jihye Lee; Lisa Kalisch Ellett
Journal:  Eur J Clin Pharmacol       Date:  2021-01-06       Impact factor: 2.953

2.  The effect of maslinic acid on cognitive dysfunction induced by cholinergic blockade in mice.

Authors:  Ho Jung Bae; Jihyun Kim; Jaehoon Kim; Nayeon Goo; Mudan Cai; Kyungnam Cho; Seo Yun Jung; Huiyoung Kwon; Dong Hyun Kim; Dae Sik Jang; Jong Hoon Ryu
Journal:  Br J Pharmacol       Date:  2020-04-01       Impact factor: 8.739

3.  Neuroinflammation Induces Neurodegeneration.

Authors:  D Kempuraj; R Thangavel; P A Natteru; G P Selvakumar; D Saeed; H Zahoor; S Zaheer; S S Iyer; A Zaheer
Journal:  J Neurol Neurosurg Spine       Date:  2016-11-18

Review 4.  Recent advances in lentiviral vectors for gene therapy.

Authors:  Xiaoyu Wang; Cuicui Ma; Roberto Rodríguez Labrada; Zhou Qin; Ting Xu; Zhiyao He; Yuquan Wei
Journal:  Sci China Life Sci       Date:  2021-07-14       Impact factor: 6.038

5.  TRA2A-induced upregulation of LINC00662 regulates blood-brain barrier permeability by affecting ELK4 mRNA stability in Alzheimer's microenvironment.

Authors:  Qianshuo Liu; Lu Zhu; Xiaobai Liu; Jian Zheng; Yunhui Liu; Xuelei Ruan; Shuo Cao; Heng Cai; Zhen Li; Yixue Xue
Journal:  RNA Biol       Date:  2020-05-06       Impact factor: 4.652

6.  Bis(ethylmaltolato)oxidovanadium (IV) alleviates neuronal apoptosis through regulating peroxisome proliferator-activated receptor γ in a triple transgenic animal model of Alzheimer's disease.

Authors:  Zhijun He; Jianxi Song; Xuexia Li; Xiaoqian Li; Huazhang Zhu; Chong Wu; Wen Xiao; Xiubo Du; Jiazuan Ni; Nan Li; Qiong Liu
Journal:  J Biol Inorg Chem       Date:  2021-07-08       Impact factor: 3.358

Review 7.  Inhibitory activities of grape bioactive compounds against enzymes linked with human diseases.

Authors:  Vagish Dwibedi; Sahil Jain; Divya Singhal; Anuradha Mittal; Santosh Kumar Rath; Sanjai Saxena
Journal:  Appl Microbiol Biotechnol       Date:  2022-02-02       Impact factor: 4.813

8.  Human Herpesvirus 6A U4 Inhibits Proteasomal Degradation of the Amyloid Precursor Protein.

Authors:  Tian Tang; Junli Jia; Emanuela Garbarino; Luyao Chen; Jingjing Ma; Peipei Li; Xiangjun Chen; Lily Wang; Yiqun Wen; Yuhang Wang; Lingyun Li; Kun Yao; Huamin Tang
Journal:  J Virol       Date:  2021-12-08       Impact factor: 6.549

9.  Dyrk1 inhibition improves Alzheimer's disease-like pathology.

Authors:  Caterina Branca; Darren M Shaw; Ramona Belfiore; Vijay Gokhale; Arthur Y Shaw; Christopher Foley; Breland Smith; Christopher Hulme; Travis Dunckley; Bessie Meechoovet; Antonella Caccamo; Salvatore Oddo
Journal:  Aging Cell       Date:  2017-08-04       Impact factor: 9.304

10.  Luteolin alleviates cognitive impairment in Alzheimer's disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation.

Authors:  Jie-Jian Kou; Jun-Zhuo Shi; Yang-Yang He; Jiao-Jiao Hao; Hai-Yu Zhang; Dong-Mei Luo; Jun-Ke Song; Yi Yan; Xin-Mei Xie; Guan-Hua Du; Xiao-Bin Pang
Journal:  Acta Pharmacol Sin       Date:  2021-07-15       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.